Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer, BioNTech to Provide US Government 500 Million Covid Vaccine Doses for Donation to Poorest Countries

06/10/2021 | 12:46am EDT

By Pietro Lombardi

Pfizer Inc. and BioNTech SE will supply the U.S. government 500 million doses of their Covid-19 vaccine at not-for-profit price for donation to poor countries.

The pharmaceutical companies said Thursday that the U.S. government will buy 200 million doses this year, while the remaining 300 million doses will be purchased next year.

The doses will go to 92 low- and lower middle-income countries.

These doses fall under the companies' previously announced pledge to provide two billion vaccine doses to low- and middle-income countries.

The first doses will be delivered in August, and the U.S. government has an option to buy additional doses next year.

Write to Pietro Lombardi at pietro.lombardi@wsj.com; @pietrolombard10

(END) Dow Jones Newswires

06-10-21 0246ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -2.96% 229.5 Delayed Quote.190.10%
DJ INDUSTRIAL -0.21% 33874.24 Delayed Quote.10.91%
PFIZER, INC. -1.41% 39.05 Delayed Quote.7.61%
All news about BIONTECH SE
03:12pMODERNAá : NIH begins clinical trial testing COVID-19 vaccine in pregnant women
RE
11:56aEuropean ADRs Edge Higher in Wednesday Trading
MT
11:49aUS' CDC To Study Possible Link Between Heart Inflammation And Pfizer/BioNTech..
MT
10:17aBIONTECHá : EMA - Two additional manufacturing sites for BioNTech Pfizer's COVID..
AQ
10:16aGLOBAL MARKETS LIVE : Microsoft, Morgan Stanley, Heineken, Twitter, AstraZeneca...
10:03aSIEMENSá : To Provide Technology Support For BioNTech's Vaccine Production Sites
MT
09:08aToday on Wall Street: We shall not be ruled by inflation fears
08:20aSiemens, BioNTech to Expand Vaccine Production Collaboration
DJ
02:11aDebate Intensifies Over A Vaccine IP Waiver's Impact On Future Pharma And Bio..
AQ
01:02aSECTORAL ASSET MANAGEMENTá : Covid-Vaccine Patent Waiver: Will it Increase World..
DJ
More news
Financials
Sales 2021 12 387 M 14 772 M 14 772 M
Net income 2021 7 065 M 8 425 M 8 425 M
Net cash 2021 7 669 M 9 145 M 9 145 M
P/E ratio 2021 7,00x
Yield 2021 -
Capitalization 47 849 M 57 117 M 57 060 M
EV / Sales 2021 3,24x
EV / Sales 2022 3,23x
Nbr of Employees 2 200
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 198,12 €
Average target price 148,37 €
Spread / Average Target -25,1%
EPS Revisions
Managers and Directors
NameTitle
Ugur Sahin Chief Executive Officer
Sierk P÷tting Chief Operating & Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Ízlem TŘreci Chief Medical Officer
Christoph Huber Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BIONTECH SE190.10%57 117
GILEAD SCIENCES, INC.15.09%84 093
WUXI APPTEC CO., LTD.36.51%68 536
REGENERON PHARMACEUTICALS10.54%55 301
VERTEX PHARMACEUTICALS-20.09%48 892
BEIGENE, LTD.28.69%30 775